20 articles
A comprehensive review reveals how the senescence secretome suppresses tumors early but drives progression, resistance, and metastasis chronically.
New research reveals cancer cells can escape therapy-induced senescence, creating a reversible drug resistance mechanism that may contribute to tumor relapse.
Study identifies senescent EGR1+ B cells that sabotage immunotherapy in esophageal cancer, with fisetin showing promise as a therapeutic enhancer.
New research reveals that whole-genome doubling triggers epigenetic changes that silence antigen presentation, letting tumors evade CD8+ T cells.
Synthetic super-enhancers hijack glioblastoma's own regulatory circuits to trigger precise, tumor-only cell death and durable immune memory.
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
Breakthrough therapy converts tumor cells into antigen-presenting cells that train immune system to destroy cancer.
Intratumoral senescent cells shielded by PD-L2 may explain why chemotherapy often falls short — and point to a new combination strategy.
New research reveals how selenium deficiency drives liver cancer progression through neutrophil aging and immune suppression.
Major study reveals how multiple cancer treatments progressively destroy immune cells, offering new insights for therapy timing.
New review reveals how HER2 reshapes the tumor immune environment — and why beating it requires more than blocking the oncogene.
New research reveals young and elderly cervical cancer patients have completely different molecular signatures requiring age-specific treatments.
Comprehensive review reveals how cancer cells manipulate immune recognition and promising therapeutic strategies to restore T cell immunity.
Scientists develop innovative immunotherapy that reprograms multiple immune cell types to attack cancer while reducing side effects.
A major review reveals how inflammaging and immunosenescence synergistically drive colorectal cancer in older adults, reshaping the tumor microenvironment.
Scientists engineered a fusion protein that recruits abundant immune cells to cross-present tumor antigens, boosting anticancer immunity in mice.
Scientists reveal how to reprogram immune cells that normally help tumors grow to instead become powerful cancer killers.
Mismatch repair-deficient cancers accumulate mutations but respond remarkably well to immune checkpoint inhibitors across tumor types.
New combination strategies show promise for overcoming immune resistance in head and neck cancers through targeted biomarker approaches.
New research reveals how progenitor cells drive the transition from benign to malignant cancer, offering potential intervention targets.
